{
    "clinical_study": {
        "@rank": "82168", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This prospective,single arm, multi-center pilot study includes 120 mRCC patients over 65\n      years, no prior systemic treatment, determined to be candidates for systemic therapy by the\n      investigator. The treatment with Sorafenib should comply with the recommendations written in\n      the local product information. The primary endpoint is overall survival.the secondary\n      endpoins including other effectiveness points, safety and patinet characteristics. With 120\n      completed patients,if the observed survival rate at 12 months is 60%, the width of a 95%\n      confidence interval will be approximately 18%."
        }, 
        "brief_title": "Sorafenib in Elderly mRCC", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Renal Cell", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically/cytologically diagnosed metastasis RCC who are\n             candidates for systemic therapy and have decided to accept Sorafenib treatment.\n\n          -  >=65 years of age\n\n          -  Patients who have signed the informed consent\n\n          -  Patients with a life expectancy of \u226512 weeks\n\n          -  No prior systemic treatment\n\n        Exclusion Criteria:\n\n          -  The approved local product lable must be followed for the exclusion criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "mRCC patients, >= 65 years of age, No prior systemic treatment, need systemic therapy"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728948", 
            "org_study_id": "16399", 
            "secondary_id": "NX1212CN"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "treatment(including dose, duration, modification) desided by the investigator", 
            "intervention_name": "Sorafenib( Nexavar, BAY43-9006)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sorafenib", 
            "renal cell carcinoma(RCC)", 
            "elderly", 
            "effectiveness", 
            "safety"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "China"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "up to 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728948"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria", 
                "safety_issue": "No", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "measure": "Disease control rate by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria", 
                "safety_issue": "No", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "measure": "Survival rate by one year", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Number of participants with adverse events( AE) and Serious adverse events(SAE) as a measure of safety and tolorability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "measure": "Patient characteristics ( Birthdate (at least year), sex, weight, height.)", 
                "safety_issue": "No", 
                "time_frame": "up to 2.5 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}